Hanmi Pharm Co Ltd

ESG Report

Report overview

The report presents Hanmi Pharm's 2022 sustainability performance alongside record consolidated sales of KRW 1.3315 trillion. It sets out a carbon-neutrality roadmap targeting Net Zero by 2040 for Scope 1 and Scope 2, supported by emissions reductions, energy management and environmental initiatives. The report also details materiality, health and safety, human rights, workforce and supply-chain programs, and reproduces independent assurance statements covering the report's sustainability data.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Energy consumption
Water consumption
Waste
Employees
Women in management
Workplace fatalities
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services